Primary Cervical Cancer Screening by Self-sampling HPV Test

Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider, which is labor consuming and the coverage and compliance are both relatively low in some areas. Non-invasive hrHPV self-sampling test appears to be more acceptable and may improve the HPV screening coverage. This study aims to evaluate the clinical performance of a newly developed urine/vaginal self-sampling hrHPV test in Cervical cancer screening.

Inclusion Criteria:a. Females aged 21-65; b. have a history of sexual life; c. The patients were voluntarily enrolled and signed the informed consent.Exclusion Criteria:Accuracy Verification:Subjects meeting any of the following criteria will be excluded:Known pregnant subjects.Participants who have undergone total hysterectomy.Participants who have received cervical resection therapy or ablative therapy within 12 months, such as cryo, laser, microwave, coagulation, cryotherapy, LEEP, large loop electrosurgery (LLETZ), cold knife conization (CKC), laser conization, or ablation.Participants with poor compliance or researchers who believe that they are not suitable to participate in this study.Primary screening use:Subjects meeting any of the following criteria will be excluded:Known pregnant subjects.Participants who have undergone total hysterectomy.Participants who have received cervical resection therapy or ablative therapy within 12 months, such as cryo, laser, microwave, coagulation, cryotherapy, LEEP, large loop electrosurgery (LLETZ), cold knife conization (CKC), laser conization, or ablation.Those with known history of cervical cancer.Participants who participated in cervical cancer screening programs or underwent cervical cytology within 12 months.Participants with poor compliance or researchers who believe that they are not suitable to participate in this study.